Tim Walberg

This resolution honors the service and sacrifice of America's veterans.

This concurrent resolution denounces socialism and opposes the implementation of socialist policies in the United States.

Fixing Emergency Management for Americans Act of 2025 or the FEMA Act of 2025

This bill reestablishes the Federal Emergency Management Agency (FEMA) (currently within the Department of Homeland Security) as an independent, cabinet-level agency. It also makes broad changes to FEMA’s disaster and hazard mitigation assistance programs.

The bill generally transfers FEMA’s current functions and authorities to the independent FEMA, except for certain security-related programs.

The bill makes various changes to the Public Assistance program, including by

• establishing new grants for expedited funding to repair or replace disaster-damaged facilities,

• establishing block grants that recipients may choose instead of Public Assistance for smaller disasters,

• expediting and expanding uses of funding for emergency response and debris removal, and

• allowing use of excess administrative funds for increasing recipients’ disaster management capacity.

The bill makes various changes to the Individual Assistance program, including by

• expanding eligibility for housing assistance,

• expanding mitigation and direct (non-financial) assistance for residences,

• reducing certain restrictions on funds duplicating program benefits, and

• establishing a unified disaster application system.

The bill makes various changes to FEMA’s mitigation programs, including by

• establishing mitigation plans with preapproved projects,

• authorizing an entire Hazard Mitigation Grant Program grant to be provided before costs are incurred,

• changing pre-disaster mitigation assistance to noncompetitive formula grants, and

• allowing recipients to combine mitigation project funds from multiple federal programs.

Additionally, federal entities must publish various information relating to disaster assistance and conduct various studies on related topics (e.g., preliminary damage assessments, fast-moving disasters, and government emergency alerting systems).

Crime Victims Fund Stabilization Act of 2025

This bill adds a new source of revenue for the Crime Victims Fund (CVF). Specifically, the bill requires certain civil monetary penalties collected from settlements and judgments in cases involving fraud and false claims against the federal government to be deposited into the CVF through FY2029.

The CVF supports federal, state, and local programs and activities to compensate and assist victims of crimes. Currently, the CVF is funded by deposits from a variety of sources, including federal criminal fines, penalties, and assessments; forfeited bail bonds; and certain other gifts, donations, and bequests.

This resolution (1) condemns the assassination of Charles "Charlie" James Kirk and all forms of political violence; and (2) honors the life, leadership, and legacy of Charlie Kirk.

Metastatic Breast Cancer Access to Care Act

This bill expedites payment of Social Security Disability Insurance (SSDI) benefits and eligibility for Medicare coverage for those with metastatic breast cancer (i.e., breast cancer that has spread to other sites in the body).

Specifically, the bill eliminates the 5-month waiting period for SSDI benefits and the subsequent 24-month waiting period for Medicare coverage for individuals with metastatic breast cancer. Under current law, individuals generally must wait 5 months after the onset of disability to begin receiving SSDI benefits and an additional 24 months to become eligible for Medicare.

DMEPOS Relief Act of 2025

This bill extends until December 31, 2025, a higher payment rate (known as the 75/25 blended rate) for durable medical equipment in nonrural or noncontiguous areas under Medicare.

Improving Seniors' Timely Access to Care Act of 2025

This bill establishes several requirements and standards relating to prior authorization processes under Medicare Advantage (MA) plans.

Specifically, MA plans must (1) establish an electronic prior authorization program that meets specified standards; (2) annually submit to the CMS for publication specified prior authorization information, including the percentage of requests approved and the average response time; and (3) meet other standards, as set by the Centers for Medicare & Medicaid Services (CMS), relating to the quality and timeliness of prior authorization determinations.

The CMS and the Office of the National Coordinator for Health Information Technology must publish on the CMS' website a report that analyzes the information received from MA plans, the feasibility of implementing real-time decision making with respect to prior authorization requests, and the impact of decisions that are made using artificial intelligence on patient access.

Sustainable Cardiopulmonary Rehabilitation Services in the Home Act

This bill permanently allows services relating to cardiac rehabilitation programs, intensive cardiac rehabilitation programs, and pulmonary rehabilitation programs to be furnished via telehealth at a beneficiary's home under Medicare.

Leveling the Playing Field 2.0 Act

This bill addresses unfair trade practices by making various changes to U.S. antidumping and countervailing duty laws. Antidumping laws provide relief to U.S industries and workers that are materially injured or threatened with injury due to imports of like products sold in the U.S. market at less than fair value, while countervailing duty laws provide such relief from imports of products subsidized by a foreign government or public entity.

Specifically, the bill establishes a process for successive antidumping and countervailing duty investigations. Successive investigations may be concurrent (an ongoing investigation of the same product) or recently completed (not more than two years before the date of the initiation of the successive investigation). Further, the bill establishes a timeline for the Department of Commerce to issue determinations in successive investigations.

Among other provisions, the bill authorizes Commerce to

• apply countervailing duty law to subsidies provided by a foreign government or public entity to a company operating in a different country,

• use another method for calculating the cost of production in specific circumstances, and

• require importers to certify that the imported merchandise is not subject to an antidumping or countervailing duty order.

Additionally, the bill statutorily establishes procedures for Commerce to conduct circumvention inquiries, including by specifying the deadlines for preliminary and final determinations.

The bill also provides statutory authority for Commerce to investigate currency undervaluation as a countervailable subsidy.

Tren de Aragua Border Security Threat Assessment Act

This bill requires the Department of Homeland Security (DHS) to submit a border threat assessment and strategic plan regarding Tren de Aragua and other transnational criminal organizations. (Tren de Aragua is a gang that originated in Venezuela.)

The threat assessment must include current and potential criminal threats from Tren de Aragua and a description of its origins, strategic aims, funding sources, and U.S. growth and presence.

DHS must submit a strategic plan not later than one year after submission of the threat assessment. The plan must include, for example, a consideration of the threat assessment and mitigation efforts regarding Tren de Aragua and other transnational criminal organizations and efforts to disseminate information between DHS and other departments, agencies, and law enforcement entities with missions associated with the border.

Accelerating Kids’ Access to Care Act of 2025

This bill requires states to establish a process through which qualifying out-of-state providers may temporarily treat children under Medicaid and the Children's Health Insurance Program (CHIP) without undergoing additional screening requirements.

Specifically, states must establish a process through which qualifying out-of-state providers may enroll for five years as participating providers to treat individuals under the age of 21 without undergoing additional screening requirements.

A qualifying out-of-state provider (1) must not have been excluded or terminated from participating in a federal health care program or state Medicaid program; and (2) must have been successfully enrolled in Medicare or a state Medicaid program based on a determination that the provider posed a limited risk of fraud, waste, or abuse.

The bill’s changes take effect three years after enactment.

Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

This bill allows, beginning in 2028, for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Coverage is limited to those under a certain age (age 68 in 2028, increased by one year every year thereafter) and to one test every 11 months.

Give Kids a Chance Act of 2025

This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.

Specifically, the bill

• modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;

• permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;

• renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and

• reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.

The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)